Early Outcome of WeFlow-JAAA Off-the-Shelf Endograft in the Treatment of Juxtarenal/Pararenal Abdominal Aortic Aneurysms.

BACKGROUND

This study was performed to evaluate the early outcomes of the WeFlow-JAAA off-the-shelf (OTS) endograft system for the treatment of juxtarenal and pararenal abdominal aortic aneurysms (JR/PR-AAAs).

METHODS

We conducted a prospective, multicenter study involving 115 patients diagnosed with JR/PR-AAAs. The inclusion criteria were a distance of ≥4 mm from the inferior edge of the superior mesenteric artery (SMA) to the aneurysm and a proximal landing zone angulation of <60°. All participants underwent endovascular repair using the WeFlow-JAAA system. The primary end points were clinical success and major adverse events (MAEs) within 30 days postprocedure. The secondary end points were all-cause mortality, secondary interventions, endoleaks, target vessel patency, and preservation of renal function during the first 30 days.

RESULTS

The patients' mean age was 69.1 years, and 94.8% were male. The average maximum aneurysm diameter was 62.7 mm. The mean proximal neck length below the SMA was 20.3 ± 8.3 mm (range: 5-50 mm). Technical success was achieved in 99.1% of patients, with a target vessel patency rate of 99.4% within 30 days. One patient (0.9%) developed an early type I endoleak. MAEs occurred in 3.5% of patients, including 1 all-cause death due to cardiac arrest and three cases of minor ischemic stroke, all of which resolved. No significant aneurysm growth or stent migration was observed.

CONCLUSION

The WeFlow-JAAA OTS endograft system demonstrated high technical success and low complication rates in the early treatment of JR/PR-AAAs. The occurrence of type II endoleaks and minor adverse events highlights areas for improvement. Future studies should focus on reducing type II endoleak risk and assessing long-term durability.